14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
DXCM vs VRTX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, DexCom, Inc. (DXCM) is the stronger overall head-to-head candidate over Vertex Pharmaceuticals Inc (VRTX) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, Options & Positioning). DXCM carries a Unified Composite Score of 50.8/100 (HOLD) at $79.32 (25.3x Forward P/E, 24.0% operating margin), whereas VRTX carries 40.9/100 (SELL) at $515.02 (25.9x Forward P/E, 37.8% operating margin).
Technical & Structure Timing Caution: DXCM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.0); meanwhile VRTX is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 40.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Medical Devices value chain with $29.9B market capitalization and 24.0% operating margin.
OpEx & R&D Reinvestment39.4% of Rev ($2.01B)
90D Engineering Disclosures0 Published
VRTX Moat ProfileHigh-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $132.0B market capitalization and 37.8% operating margin.
OpEx & R&D Reinvestment17.0% of Rev ($2.20B)
90D Engineering Disclosures0 Published
Investor FAQ DXCM vs VRTX Key Questions & Quantitative Answers
As of Nov 20, 2026, DexCom, Inc. (DXCM) is the stronger overall head-to-head candidate over Vertex Pharmaceuticals Inc (VRTX) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, Options & Positioning). DXCM carries a Unified Composite Score of 50.8/100 (HOLD) at $79.32 (25.3x Forward P/E, 24.0% operating margin), whereas VRTX carries 40.9/100 (SELL) at $515.02 (25.9x Forward P/E, 37.8% operating margin). Technical & Structure Timing Caution: DXCM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.0); meanwhile VRTX is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 40.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
VRTX leads the Growth & Scale pillar: DXCM posts +11.2% YoY revenue growth and +2.6% YoY earnings growth on $5.10B TTM revenue (63.4% gross margin, 24.0% operating margin), compared with VRTX at +11.8% YoY revenue growth and -39.0% YoY earnings growth on $13.0B TTM revenue (54.8% gross margin, 37.8% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), DXCM cumulative revenue shifted +352.4% while VRTX shifted +293.4%. In operating R&D and SG&A reinvestment, DXCM deploys 39.4% of Rev ($2.01B) (0 90-day corporate R&D disclosures) versus 17.0% of Rev ($2.20B) (0 disclosures) for VRTX.
DXCM screens cheaper on headline valuation multiples. DXCM trades at 25.3x Forward P/E, 31.6x Trailing P/E, 1.30x PEG, and 5.9x EV/Revenue (33.9% FCF margin), whereas VRTX trades at 25.9x Forward P/E, 33.5x Trailing P/E, 2.34x PEG, and 10.3x EV/Revenue (24.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DXCM (37.7% ROE) versus VRTX (20.8% ROE) capital efficiency.
In options market volatility and institutional positioning, DXCM carries 63.0% implied volatility (15th %ile, Compressed (<25th %ile)), a 0.48x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.59β · 43% Vol realized risk). By comparison, VRTX carries 115.6% implied volatility (33rd %ile, Balanced (25th–60th %ile)), a 1.00x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.35β · 28% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.